Interim Report 1 July – 30 September 2021
· Strategy updated to include two products targeting 510(k)-approval · Published data from first comparative study and first study with 5-year follow-up from Episealer® · Directed share issue executed, raising SEK 159 million – funding until 2025 secured ”We are currently seeing high activity across the business with several initiatives ongoing within our commercialisation, clinical activities and product development. As already communicated, we experienced certain COVID-19 related effects during the quarter that we cannot disregard, but all in all we are taking important steps in